TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE: TheraSphere Y-90 glass microsphere therapy
DRUG: Durvalumab (Imfinzi) immunotherapy
DRUG: Tremelimumab immunotherapy

Sponsor

Boston Scientific Corporation

Collaborators

[object Object]